Prostate cancer screening for men over 70 is complex, with current recommendations against routine PSA testing due to slow ...

NICE recommends Bayer’s Nubeqa® (darolutamide) plus androgen deprivation therapy as a treatment option for patients with hormone-sensitive metastatic prostate cancer Nubeqa® (darolutamide) plus ...

GSK has acquired the rights to Syndivia’s preclinical antibody drug conjugate (ADC), which is in development for prostate ...

GSK is set to acquire the exclusive rights for Syndivia’s preclinical antibody-drug conjugate (ADC), which is currently in ...

A new drug combination cuts the risk of death in people with advanced prostate cancer by 40% over eight years, according to ...

A globally-renowned prostate cancer surgeon shares the latest advancements in the field and stresses the importance of early ...

The combination of niraparib and abiraterone halves the spread of prostate cancer in men with BRCA gene mutations.

A new phase 3 trial reveals that combining enzalutamide and leuprolide significantly improves overall survival for men with ...

New findings from the EMBARK trial reveal enzalutamide significantly reduces mortality risk in high-risk prostate cancer ...

The Nubeqa (darolutamide) regimen can be used to treat adult patients with advanced HSPC if docetaxel, a chemotherapy agent, ...

Anti-tumor activity was observed in heavily pretreated mCRPC patients across all dose cohorts; in 22 patients who completed ...